Filing Flows › Angiodynamics (ANGO) › Q4 FY25
Angiodynamics (ANGO) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jul 18, 2025
Angiodynamics (ANGO) reported revenue of $80.2M for the fourth quarter fiscal 2025 (Q4 FY25), +13% from a year earlier and +11% from the quarter before. Operating margin was -7.2%, net loss $6.0M (7.5% of revenue).
Angiodynamics, Q4 FY25: revenue $80.2M (+13% year over year), operating margin -7.2%, net loss $6.0M, operating cash flow $18.8M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $80.2M | +11% | +13% |
| Operating profit | −$5.8M | — | — |
| Net earnings | −$6.0M | — | — |
| Operating cash flow | $18.8M | — | +276% |
| Free cash flow | $18.0M | — | +307% |
What changed
Revenue was $80.2M in Q4 FY25, up 13% year over year and up 11% from the previous quarter.
Gross margin was 52.7%, down 1.6 points from a year earlier. Operating costs exceeded revenue by $5.8M, an operating margin of -7.2%. Operating expenses fell 9% while revenue rose 13%. The quarter ended with a net loss of $6.0M, wider than the previous quarter's $4.4M loss.
Operating cash flow was $18.8M (up 276% year over year). Non-cash charges added back $5.8M of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items added $17.4M. Capital expenditures of $777K left free cash flow of $18.0M.
Questions
What was Angiodynamics' revenue in the fourth quarter fiscal 2025?
Angiodynamics (ANGO) reported revenue of $80.2M for the fourth quarter fiscal 2025 (Q4 FY25), +13% from a year earlier and +11% from the quarter before.
Was Angiodynamics profitable in the fourth quarter fiscal 2025?
Operating loss was $5.8M (-7.2% of revenue) and net loss $6.0M.
Source: Angiodynamics 10-K on SEC EDGAR.